

# ForPatients

by Roche

Fallopian Tube Cancer Primary Peritoneal Cancer Ovarian Cancer

## A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03635489 YO40268

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and carboplatin compared with placebo plus paclitaxel and carboplatin in Chinese participants with newly diagnosed, previously untreated Stage III or Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants whose disease has not progressed after six cycles of paclitaxel and carboplatin with either bevacizumab or placebo will continue treatment with either bevacizumab or placebo until disease progression, unacceptable toxicity, or a maximum of 22 cycles, whichever occurs first.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03635489 YO40268**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
Female

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---